Unlocking the Therapeutic Potential of Amylin-Based Therapies for Obesity
Unlocking the Therapeutic Potential of Amylin-Based Therapies for Obesity
Playbook
Obesity is a chronic, progressive, and relapsing disease that imposes a substantial clinical burden. Despite the availability of approved pharmacologic agents with varying mechanisms of action, efficacy, tolerability, and accessibility, only a small percentage of eligible patients are prescribed evidence-based medications, often due to clinician knowledge gaps, concerns regarding long-term safety, and a persistent but inaccurate perception of obesity as a failure of willpower rather than a multifactorial neuroendocrine disorder. Clinicians also encounter significant limitations with available therapies, including suboptimal weight loss efficacy, heterogeneous patient responses, and the difficulty of maintaining weight reduction after treatment discontinuation.
Diverse emerging neuroendocrine therapies targeting multiple metabolic pathways, such as amylin, are under investigation for obesity management. Clinicians require enhanced understanding of the complex physiology, central and peripheral mechanisms, and evolving clinical evidence supporting amylin-based therapies to counsel patients and integrate these emerging strategies into future obesity treatment approaches.
In this interactive playbook, clinicians can navigate neuroendocrine physiology, mechanisms of action, and latest clinical evidence on amylin-based therapies for obesity. Expert perspectives help put the data into context and frame future care paradigms.
Faculty: Domenica M. Rubino, MD
Release Date:
Expiration Date: August 07, 2027
